HF 1047

as introduced - 91st Legislature (2019 - 2020) Posted on 03/09/2020 05:56pm

A bill for an act
relating to health; establishing a pharmacogenomics grant program; proposing
coding for new law in Minnesota Statutes, chapter 144.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

new text begin [144.1477] PHARMACOGENOMICS (PGX) GRANT PROGRAM.
new text end

new text begin Subdivision 1. new text end

new text begin Grants. new text end

new text begin Within limits of available appropriations, the commissioner of
health shall award grants to persons, organizations, and entities that apply for a grant under
this subdivision to fund research studies on the evidence needed to: (1) support payer
reimbursement and funding of PGx testing; (2) determine and validate new PGx variants
in diverse populations such as Native Americans and Somali groups; (3) determine ethical,
legal, and social implications of PGx; (4) determine the technical aspects needed to protect
data and privacy as it relates to PGx; and (5) determine the education needed for successful
PGx implementation.
new text end

new text begin Subd. 2. new text end

new text begin Allocation of grants. new text end

new text begin To receive a grant under this section, an applicant must
submit an application on a form and in the manner specified by the commissioner of health.
The applicant must submit the application by the deadline established by the commissioner.
The commissioner shall require at a minimum the following information from the applicant:
new text end

new text begin (1) a description of achievable objectives, a work plan, budget, budget narrative, a project
communication plan, a timeline for implementation and completion of processes or projects
enabled by the grant, and an assessment of privacy and security issues and a proposed plan
to address the issues specified in subdivision 1;
new text end

new text begin (2) a plan for how patients and consumers will be involved in development of policies
and procedures related to the access and interchange of relevant information;
new text end

new text begin (3) a plan for documenting and evaluating results of the grant; and
new text end

new text begin (4) a plan for use of data exchange standards as the data relates to sharing testing results,
including standardized terminology to be used when sharing data.
new text end

new text begin Subd. 3. new text end

new text begin Eligible grantees. new text end

new text begin Persons, organizations, and entities eligible to receive grant
funding under this section include those that:
new text end

new text begin (1) have expertise in pharmacogenomics;
new text end

new text begin (2) are expert data analysts in the pharmacogenomics market; and
new text end

new text begin (3) specialize in pharmacogenomic research.
new text end

new text begin Subd. 4. new text end

new text begin Consultation. new text end

new text begin In awarding grants under subdivision 1, the commissioner shall
follow the grants management protocols in section 16B.97 and consult with interested parties
who are able to provide technical information, advice, and recommendations on grant
projects and awards. Interested parties include but are not limited to persons or private and
public entities with expertise in pharmacogenomics.
new text end